Topic: autoimmune disease
Pandion and Astellas inked a deal to discover, develop and market bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas.
Neither trial hit the primary endpoint, although Gilead did see “evidence of activity” in patients taking filgotinib.
Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.
Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.
University of Pennsylvania scientists designed CAAR-T cells to only target the cells that express autoantibodies in autoimmune diseases.
The series A round will bankroll efforts to develop antibodies that treat autoimmune diseases by stimulating specific immune cell signals.
HSAC will buy the Roivant business but the resulting company will take Immunovant’s name, management team and strategic focus.
GlaxoSmithKline has struck a deal to buy Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures.
Quell has brought together experts in multiple fields to probe a question with far-reaching implications: What would happen if we applied CARs and other cell enhancements to regulatory T cells rather than effector T cells?
Two dose levels of Concert's alopecia drug beat placebo in phase 2, teeing it up to enter phase 3 in 2020.